Binaytara Foundation Cancer Center in Nepal Updates Hematology Lab For Improved Diagnostic Capabilities

For more information contact:

Tara Shah

(425) 557-5953

support@binayfoundation.org

Janakpurdham, Nepal, April 9, 2022 – As part of its planned expansion to serve the community of cancer patients in Nepal’s Province 2 and neighboring areas, the Binaytara Foundation Cancer Center (BTFCC) has upgraded its Hematology Lab with equipment that will allow faster, more accurate diagnostic capabilities.

The Yumizen H500 is a compact hematology system that provides highly accurate and reliable blood test results. It offers 27 hematology parameters, including a full WBC differential with 6 WBC populations. Whole blood sampling is available, and doctors will be able to receive patients’ test results in half the time.

With so many patients in Nepal and India in need of cancer care, it’s essential that our staff complete tests and view test results as quickly as possible. We’re very pleased to begin using the Yumizen H500, as hematology labs are critically important in cancer care.”

Dr. Binay Shah, President, Binaytara Foundation

Reliable, swift and accurate test results are critical for high quality cancer care,” says Binaytara Foundation president Dr. Binay Shah. “With so many patients in Nepal and India in need of cancer treatment, it’s essential that our staff complete tests and view test results as quickly as possible. We’re very pleased to begin using the Yumizen H500, as hematology labs are critically important in cancer care” Dr Shah added.

The Binaytara Foundation Cancer Center’s immediate expansion is intended to quadruple the hospital’s capacity, providing care for the more than 25 million residents of Nepal and surrounding areas. Prior to the cancer center’s opening in 2018, many cancer patients in Madhesh Province (formerly known as Province 2) had to leave behind their family and friends, traveling more than eight hours, to seek treatment. Often they had to visit a hospital in an area where few people spoke their language, and the lengthy trip wasn’t an option for those cancer patients in Nepal due to a lack of resources or time. Since opening, the Binaytara Foundation Cancer Center in Nepal has worked to keep up with demand, and recently the board decided to build a larger center to better meet patient needs.

Meanwhile, improvements like the addition of the Yumizen H500 continue to reduce wait times for patient tests and elevate the high-quality patient care already offered at BTFCC.

About Binaytara Foundation:

Binaytara Foundation is a global cancer non-profit dedicated to improving access to cancer care in the United States and abroad through education and innovative program models that break down barriers and advance best practices in hematology and oncology. Binaytara Foundation’s major projects include hematology and oncology conferences, and the establishment of a cancer hospital in Nepal.

Staff Writer - The Cancer News

Recent Posts

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)

By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. Department of Internal Medicine, University of Central…

5 months ago

ASCO24 LAURA Trial Summary

By: Zhiting Tang1, Lei Deng21. Unity Hospital, Rochester Regional Health, Rochester, NY2. University of Washington/Fred…

5 months ago

FDA Approves Tovorafenib for Pediatric Low-Grade Glioma With BRAF Mutation

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

6 months ago

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 29, 2024, the U.S. Food and Drug…

6 months ago

FDA Approves Lutetium Lu 177 Dotatate for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

6 months ago

FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 18, 2024, the U.S. Food and Drug…

6 months ago